Compare CYTK & XP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CYTK | XP |
|---|---|---|
| Founded | 1997 | 2001 |
| Country | United States | Cayman Islands |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Bankers/Brokers/Service |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.4B | 8.9B |
| IPO Year | 2004 | 2019 |
| Metric | CYTK | XP |
|---|---|---|
| Price | $78.68 | $15.34 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 19 | 6 |
| Target Price | ★ $89.26 | $23.17 |
| AVG Volume (30 Days) | 1.7M | ★ 5.8M |
| Earning Date | 05-05-2026 | 05-19-2026 |
| Dividend Yield | N/A | ★ 0.98% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $13,368,000.00 | N/A |
| Revenue This Year | $7.37 | $19.00 |
| Revenue Next Year | $310.19 | $13.64 |
| P/E Ratio | ★ N/A | $11.42 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $31.99 | $14.80 |
| 52 Week High | $80.20 | $23.13 |
| Indicator | CYTK | XP |
|---|---|---|
| Relative Strength Index (RSI) | 62.37 | 36.89 |
| Support Level | $59.07 | $14.80 |
| Resistance Level | $79.66 | $20.21 |
| Average True Range (ATR) | 3.20 | 0.55 |
| MACD | 0.51 | 0.05 |
| Stochastic Oscillator | 83.65 | 19.02 |
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
XP Inc is a Cayman Island-based technology-driven financial services platform. It is a provider of low-fee financial products and services in Brazil. The company evaluates its business through a single segment such as monitoring operations, making decisions on fund allocation, and evaluating the performance. It generates revenue through the Brokerage commission. Geographically, the company derives maximum revenue from Brazil and also has its presence in other countries.